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The Chronic GVHD ConsortiumIn 2005, the National Institutes of Health sponsored a Consensus Development Project on Criteria for Clinical
Trials in chronic graft-versus-host (cGVHD) to achieve consensus about key elements of cGVHD research,
including definitions for diagnosis, severity scoring, and response measures. To test these proposed definitions,
a multicenter prospective cohort study of people with cGVHD is ongoing. This study will evaluate the perfor-
mance of proposed prognostic factors, measures of disease activity, and surrogate endpoints for therapeutic
response. Data are collected at 6-month intervals in a heterogeneous population of patients reflecting modern
transplant techniques and posttransplantation clinical management (target enrollment 672with cGVHD from10
transplantation centers). This report describes the rationale, design, and methods of the cGVHD cohort study,
and invites other investigators to collaborate with the Consortium to analyze data or specimens.
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Chronic graft-versus-host disease (cGVHD) is
a common immune-mediated disorder following allo-
geneic hematopoietic cell transplantation (HCT), oc-
curring in 30% to 70% patients [1,2]. Historically,
cGVHD was distinguished from acute GVHD
(aGVHD) based on its occurrence beyond day 100
after HCT, and severity was classified as limited or
extensive based on target organ involvement [3].
Skin, mouth, eye, and liver are historically the most
frequently involved organs [4,5]. Chronic GVHD is
associated with worse quality of life [6-8], prolonged
duration of immunosuppressive therapy [9], and
higher nonrelapse mortality (NRM), but also a lower
relapse rate [10].
Although cGVHD is associatedwith highmorbidity
andmortality followingHCT, little substantive progress
has been made over the last 3 decades. The National In-
stitutes of Health (NIH) organized a consensus confer-
ence in 2005 aimed at consolidating expert opinion to
standardize approaches to diagnosis, scoring, histopa-
thology, biomarkers, response assessment, and the con-dence and reprint requests: Stephanie J. Lee, MD, MPH,
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6/j.bbmt.2011.05.007duct of clinical trials in cGVHD [11-16]. It was
acknowledged that collection of prospective data was
necessary for validation of these recommendations, and
future modifications were anticipated as data became
available.
The Chronic GVHD Consortium is conducting
amulticenter, prospective, longitudinal study designed
to validate and refine the recommendations of the
NIHConsensus Conference, and to provide improved
tools for clinical trials in cGVHD.This article outlines
the design and methods of the Chronic GVHD Co-
hort study, describes the first 546 enrolled patients,
and provides information about accessing materials
and data from the study.METHODS
Objectives
The study has 2 major objectives: (1) evaluate
whether prognostic measures at onset of cGVHD pre-
dict overall and disease-free survival (DFS), NRM, and
functional impairment; (2) evaluate proposed measures
of cGVHDdisease activity for association with (a) short-
term outcomes, including changes in cGVHD medica-
tions, clinician grading of cGVHD severity and change,
and patient self-assessment of cGVHD severity and
change; and (b) long-term outcomes, including overall
survival (OS), time to discontinuation of systemic im-
munosuppressive therapy, and functional impairment.
Figure 1. Location of enrolling centers in the Chronic GVHD Consor-
tium.
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viders and patients will address the limitations of prior
studies that relied on medical chart review.
Population
Allogeneic HCT recipients were eligible for inclu-
sion in this study if theywere 2 years or older, had a clin-
ical diagnosis of cGVHD (overlap syndrome with
concurrent manifestations of both cGVHD and
aGVHD was allowed), and were receiving systemic
treatment for cGVHD, defined as anymedication or in-
tervention delivered systemically, including extracorpo-
real photopheresis. Any graft source, donor type, and
GVHD prophylaxis was allowed. Prevalent cases (de-
fined as enrollment 3 ormoremonths after cGVHDdi-
agnosis) were within 3 years of stem cell infusion.
Incident cases (enrollment less than3months after diag-
nosis) had no limitation on time from transplantation.
Patients were excluded if they were unable to comply
with study procedures, had evidence of primary disease
relapse, or had an anticipated survival less than6months
because of comorbid disease. At FredHutchinson Can-
cer Research Center, a limited number of patients with
late-onset, persistent, or recurrent aGVHD were also
enrolled (n 5 9) [12] as were control patients without
cGVHD as a comparison group (n 5 42). In order to
be considered a control, participants had no diagnostic
criteria for cGVHD and did not develop any in the
3months after enrollment. Controls may still be receiv-
ing systemic immune suppressive medications for pro-
phylaxis or treatment of aGVHD. The protocol is
institutional review board (IRB)-approved at all partici-
pating sites, and all participants provided written in-
formed consent. This study was registered at
www.clinicaltrials.gov as #NCT00637689. Participat-
ing transplantation centers and investigators are listed
in the Appendix (Figure 1).
Study Design
This is a prospective, longitudinal observational
study. No therapeutic interventions are mandated by
the protocol. Target enrollment is 672 patients at 10
transplantation centers. Unfortunately, the Consor-
tium is unable to accept new sites.
At the time of enrollment and every 6 months, pro-
viders and patients provide standardized information
about organ involvement and symptoms. Incident cases
have an additional assessment at 3 months after enroll-
ment. Chart review is used to document objective med-
ical data (including ancillary testing and laboratory
results), medical complications, and medication profiles
(Table 1). Serial assessments are performed until recur-
rent malignancy develops requiring immunotherapy
(rapid tapering of immunosuppression or donor lym-
phocyte infusions) or antineoplastic therapy, cGVHD
resolves for 1 year, or the endof the study, whichever oc-curs first. Patients who are not seen at the transplant
center for their semiannual assessments are sent the
patient-reported surveys bymail and outsidemedical re-
cords are reviewed for clinical information, but no pro-
vider assessment form is collected.Data Collection
Data are entered into an electronic database main-
tained at the Coordinating Center at Fred Hutchinson
Cancer Research Center using only a study identifica-
tion number (ID). Data are cleaned every 3 months us-
ing customized programs for range and logic checking,
and by random audits comparing entry to source doc-
uments.
Provider assessment form
Providers report data as recommended by theNIH
Consensus Conference for cGVHD individual organ
involvement, as well as the presence of specific findings
such as bronchiolitis obliterans syndrome. Providers
report a global rating of current disease severity
(mild, moderate, or severe; and 0-10) and perceptions
of change (a 1-8 scale from ‘‘completely resolved’’ to
‘‘verymuchworse’’). Additional items that are collected
even though they were not recommended by the NIH
Consensus Conference include reasons for medication
changes, justification of the global rating score, an
overall assessment of response (complete response,
partial response, stable, or progression), perceptions
of disease activity, and identification of a sentinel organ
to judge success of therapy. Providers also complete
endpoint measures used in previous cGVHD clinical
studies such as the JohnsHopkins items for skin, fascia,
andmouth involvement [17] and theVienna Skin Score
[18,19]. The battery of provider forms takes
approximately 10 minutes to complete once the
physical exam and interview are completed. Online
Table 1. Data Collection for the Cohort Study
Data Element Data Source Description
Provider assessment form Clinical providers NIH organ scores, Johns Hopkins organ scores, Vienna skin
score, NIH response measures, range of motion, overall
chronic GVHD severity, sentinel organ, reason for
adjusting treatment, rare clinical manifestations,
perceptions of change
Patient assessment form Patients FACT-BMT, SF-36, Lee symptom scale, HAP, ODSI, ASK,
overall chronic GVHD severity, perceptions of change
Functional assessments Patients FEV1 via portable spirometer, grip strength, 2-minute walk
test, Schirmer’s test
Chart review Institutional database or medical records Patient, donor, and transplant characteristics,
immuosuppressive medications, comorbidity, biopsy
dates, number of hospital days, relapse, death, resolution
of chronic GVHD
Biological samples Limited institutions Serum, plasma, peripheral blood mononuclear cells, urine
GVHD indicates graft-versus-host disease; FACT-BMT, functional assessment of cancer therapy-bone marrow transplant version 4.0; SF-36, short
form-36 v2.0; HAP, human activities profile; ODSI, ocular disease surface index; ASK, Activities Scale for Kids; FEV1, forced expiratory volume, first
second.
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forms is available on the Web [20,21].
Functional assessments
Clinical or study staff perform and record func-
tional status measures. Grip strength is measured 3
times from the dominant hand using a portable elec-
tronic dynamometer. Threemeasures of forced expira-
tory volume, first second (FEV1) are recorded using
a portable spirometer. The 2-minute walk test requires
the patient to walk a 50-foot course (25 feet each direc-
tion), and the total distance covered after 2 minutes is
recorded. Finally, bilateral Schirmer’s test is per-
formed without anesthesia. Of these tests, the grip
strength, walk test, and Schirmer’s test are recommen-
ded by the NIH Consensus Conference. The func-
tional testing takes approximately 20 minutes to
collect.
Patient assessment form
Patients report their symptoms, global severity
scores, perceptions of change, quality of life, and func-
tional status. The Functional Assessment of Cancer
Therapy-Bone Marrow Transplant subscale (FACT-
BMT), SF-36, Chronic GVHD Symptom Scale,
Human Activities Profile, and Activities Scale for Kids
(ASK) (pediatrics only) are collected, as recommended
by the consensus conference [14]. In addition, patients
complete the Ocular Surface Disease Index (OSDI).
Scoring follows the recommendations of the developers
but generally follows the tenet that a subscale or scale
can be scored if more than 50% of the data are present.
The battery of patient forms takes approximately 20 to
30 minutes to complete.
The FACT-BMT version 4 is a 49-item self-report
questionnaire, which includes a 12-item Bone Marrow
Transplant subscale. Patients respond based on their
experience over the preceding 7 days. The instrumentmeasures the effect of cancer therapy on multiple
quality-of-life (QOL) domains including physical,
functional, social/family, and emotional well-being,
and bone marrow transplantation (BMT) specific con-
cerns. Individual domain scores are summarized to give
a total FACT-BMT score, with higher scores indicat-
ing greater quality of life. Abbreviated scores, which
can be derived from these data, include a FACT-G
summarymeasure that excludes the BMT-specific sub-
scale, and the FACT-TOI (trial outcome index) score,
which consists of the sum of physical and functional
well-being and the BMT subscale. The FACT-BMT
has been extensively used in investigation ofQOL after
HCT [22].
The Medical Outcomes Study Short Form version
2.0 (SF-36) is a 36-itemself-report questionnaire that as-
sesses general health and functioning. The instrument
examines 8 domains of QOL: physical functioning,
role functioning-physical, bodily pain, general health,
vitality, social functioning, role functioning-emotional,
and mental health. Scores range from 0 to 100, with
higher scores indicating better functioning. Two sum-
mary scales from the SF-36 include the physical compo-
nent score (PCS) and the mental component score
(MCS), which are normalized to the general population
with amean of 50 and standard deviation of 10. The SF-
36 has been extensively utilized in diverse biomedical
research [23,24].
The Chronic GVHD Symptom Scale is a 30-item,
7-subscale symptom scale developed to capture the
symptom burden of patients with cGVHD. The in-
strument evaluates adverse effects of cGVHD on
skin, vitality, lung, nutritional status, psychological
functioning, eye, and mouth by asking patients to re-
port the degree of bother they experienced in the
past month from their cGVHD symptoms. Scores
range from 0 to 100 with higher scores indicating
greater symptom burden [25].
Biol Blood Marrow Transplant 17:1114-1120, 2011 1117Rationale and Design of the Chronic GVHD Cohort StudyThe Human Activity Profile (HAP) is a 94-item
self-reported assessment of energy expenditure and
physical fitness. TheHAPwas first developed in a pop-
ulation with pulmonary disease [26], and has since
been utilized in multiple other chronic health condi-
tions. The HAP has been validated in an HCT popu-
lation [27]. Two scores are calculated: a maximum
activity score (MAS) and an average activity score
(AAS). An HCT-specific modified score has been pro-
posed [27].
The Ocular Surface Disease Index (OSDI) is a 12-
item validated scale that captures dry eye symptoms
[28].
The ASK is a 38-item pediatric measure of physical
disability intended for children from 5 to 15 years of
age. Questions may be read to nonreaders. There are
9 subdomains: personal care, dressing, eating and
drinking, locomotion, stairs, play, transfers, standing
skills, and miscellaneous items [29,30].
Medical records abstraction
Information on patient, donor, and transplantation
characteristics, cGVHD presentation, and current sta-
tus is collected from institutional databases or chart re-
view. Immunosuppressive medications at the time of
the visit and any given between visits are captured. Co-
morbidities are recorded at the onset of cGVHD, at
the time of enrollment, and when a patient goes off
study using items from the Sorror comorbidity index
[31] and the functional comorbidity index [32].
Biological samples
At selected institutions, biological samples are also
banked in a repository for future studies. For example,
at the Fred Hutchinson Cancer Research Center,
plasma, serum, peripheral blood mononuclear cells,
and urine samples are stored and available by request.
Investigators may also access skin biopsy specimens
previously collected for clinical purposes. Stanford,
University of Minnesota, Dana-Farber Cancer Insti-
tute, and Vanderbilt University have repositories; in-
terested investigators should contact individual site
Principal Investigators to arrange collaborations.Biostatistical Considerations
This is a longitudinal observational study with 1
baseline and a variable number of follow-up assess-
ments for each participant. Information from this
study will be used to learn how we can most effectively
and efficiently assess and document clinical benefit in
trials testing new treatment interventions in patients
with cGVHD. These determinations will be made
based on the following considerations: the extent to
which each scale provides reliable and unique informa-
tion about meaningful outcomes; respondent burden(either provider or patient); and costs and resource uti-
lization required to collect the item.
Missing data are inevitable in any clinical study.
Each analysis of study data will describe missing
data, examine mechanisms of ‘‘missingness,’’ and at-
tempt to account for them. These methods include
a comparison of those with and without missing data,
documentation of sources of missing data, and evalua-
tions of the pattern of missingness. Centralized
multiple imputation of selected variables could be per-
formed in the future [33,34].Collaboration with Other Investigators
The consortium collaborates with other investiga-
tors who wish to access curated data and research sam-
ples derived from this study. Before data or samples
can be provided, a concept sheet must be discussed
by Consortiummembers and approved by the Consor-
tium Principal Investigator. All ancillary studies re-
quire IRB approval or waiver at both the center(s)
providing data/samples and the receiving institu-
tion(s), as well as a materials transfer agreement or
data use agreement if a subcontract is not in place. Ap-
proval of the collaboration by the National Cancer In-
stitute may also be required. Data are deidentified,
with clinical information and samples designated
only by a study ID.Baseline Characteristics of Cohort
As of March 2011, a total of 546 subjects have
been enrolled in this prospective cohort study
from 9 transplantation centers. Patient sociodemo-
graphics, cGVHD case type, and transplantation
variables are summarized in Table 2.SUMMARYAND CONCLUSIONS
The Chronic GVHD Cohort Study aims to im-
prove outcome assessment in cGVHD. This study
will evaluate the natural history of cGVHD under
modern treatment regimens, and will evaluate prog-
nostic factors, potential measures of disease activity,
and surrogate endpoints for therapeutic response.
The study has a number of strengths including its
size, prospective and standardized data collection, and
the availability of biologic samples from approximately
one-half of participants. Enrollment at many geo-
graphically disparate transplantation centers ensures
that different management styles and transplantation-
related factors are well represented. The study also
has a number of weaknesses including that treatment
is not standardized and provider-reported data are
only as good as the training and experience of the clini-
cian. This study is conducted in the midst of clinical
practice, so that patients do not always return when
Table 2. Enrollment Sociodemographic, Chronic GVHD, and Transplantation Characteristics (N 5 546)
Characteristic
Chronic GVHD
(n 5 495)
Controls, No Chronic GVHD
(n 5 42)*
Persistent, Recurrent, or Late
Acute GVHD (n 5 9)
n (%) n (%) n (%)
Case type
Incident 283 (57%) — —
Prevalent 212 (43%) — —
Adult (18+) 481 (97%) 42 (100%) 9 (100%)
Patient age at registration (years)
Median (range) 51 (2-79) 51 (22-72) 51 (28-61)
Male patients 288 (58%) 19 (45%) 9 (100%)
Hispanic patients 24 (5%) 3 (7%) 0 (0%)
Diagnosis at transplant
AML 151 (33%) 10 (27%) 2 (22%)
ALL 57 (13%) 5 (13%) 1 (11%)
CML 25 (6%) 1 (3%) 0 (0%)
CLL 34 (7%) 1 (3%) 1 (11%)
MDS 69 (15%) 7 (19%) 3 (33%)
NHL 66 (14%) 5 (13%) 0 (0%)
HD 16 (3%) 2 (6%) 0 (0%)
MM 21 (5%) 5 (13%) 2 (22%)
AA 5 (1%) 0 (0%) 0 (0%)
Other 15 (3%) 1 (3%) 0 (0%)
Disease status
Early 149 (33%) 12 (32%) 3 (33%)
Intermediate 196 (43%) 12 (32%) 5 (56%)
Advanced 110 (24%) 13 (36%) 1 (11%)
Graft source
Peripheral blood 405 (88%) 29 (78%) 5 (56%)
Bone marrow 34 (7%) 7 (19%) 1 (11%)
Cord blood 22 (5%) 1 (3%) 3 (33%)
Transplant type
Myeloablative 261 (57%) 20 (54%) 3 (38%)
Not myeloablative 193 (43%) 17 (46%) 5 (62%)
Patient CMV positive 261 (57%) 15 (41%) 5 (56%)
Donor CMV positive 180 (40%) 15 (41%) 2 (22%)
Donor type
HLA matched relative 199 (44%) 19 (51%) 3 (33%)
HLA mismatched relative 10 (2%) 5 (14%) 0 (0%)
Unrelated donor 249 (54%) 13 (35%) 6 (67%)
Site
Fred Hutchinson Cancer Research Center 229 (46%) 42 (100%) 4 (44%)
University of Minnesota 56 (11%) 0 (0%) 5 (56%)
Dana-Faber Cancer institute 58 (12%) 0 (0%) 0 (0%)
Stanford University Medical Center 68 (13%) 0 (0%) 0 (0%)
Northwestern Children’s Hospital 13 (3%) 0 (0%) 0 (0%)
Vanderbilt University Medical Center 39 (8%) 0 (0%) 0 (0%)
Medical College of Wisconsin 16 (3%) 0 (0%) 0 (0%)
Washington University 3 (1%) 0 (0%) 0 (0%)
Moffitt Cancer Center 13 (3%) 0 (0%) 0 (0%)
Patient race
White 442 (89%) 40 (96%) 7 (78%)
Black 13 (2%) 1 (2%) 0 (0%)
Asian 26 (5%) 0 (0%) 1 (11%)
American Indian/Alaskan Native 1 (1%) 1 (2%) 0 (0%)
Native Hawaiian/Pacific Islander 2 (1%) 0 (0%) 0 (0%)
Multi 6 (1%) 0 (0%) 0 (0%)
Unknown 5 (1%) 0 (0%) 1 (11%)
Donor gender
Female into male 130 (29%) 5 (13%) 1 (11%)
Mixed (cord blood) 9 (2%) 1 (3%) 0 (0%)
Other combinations 317 (69%) 31 (84%) 8 (89%)
Marital status
Married/living with partner 314 (77%) 20 (62%) 5 (72%)
Single, never married 33 (8%) 5 (16%) 1 (14%)
Divorced, separated 45 (11%) 5 (16%) 1 (14%)
Widowed 11 (3%) 2 (6%) 0 (0%)
Other 4 (1%) 0 (0%) 0 (0%)
Highest education
Grade school 7 (2%) 0 (0%) 0 (0%)
Some high school 13 (3%) 0 (0%) 0 (0%)
High school graduate 66 (16%) 2 (6%) 1 (14%)
Some college 121 (29%) 5 (16%) 4 (58%)
(Continued )
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Characteristic
Chronic GVHD
(n 5 495)
Controls, No Chronic GVHD
(n 5 42)*
Persistent, Recurrent, or Late
Acute GVHD (n 5 9)
n (%) n (%) n (%)
College graduate 113 (27%) 15 (49%) 1 (14%)
Post-graduate degree 96 (23%) 9 (29%) 1 (14%)
Annual family income
Under $15,000 16 (4%) 2 (7%) 0 (0%)
$15,000-$24,999 27 (7%) 1 (4%) 1 (14%)
$25,000-$49,999 60 (16%) 7 (24%) 1 (14%)
$50,000-$74,999 79 (21%) 5 (17%) 4 (58%)
$75,000-$99,999 62 (16%) 5 (17%) 1 (14%)
$100,000 or above 137 (36%) 9 (31%) 0 (0%)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS,
myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; HD, Hodgkin’s disease; MM, multiple myeloma; AA, aplastic anemia; CMV, cytomegalovirus;
HLA, human leukocyte antigen.
*Eight patients are awaiting confirmation as controls.
Biol Blood Marrow Transplant 17:1114-1120, 2011 1119Rationale and Design of the Chronic GVHD Cohort Studydesirable and clinician time and resources limit exten-
sive evaluations.
Investigators interested in the clinical data, re-
search forms, database structure, or research samples
available from this cohort study should contact the
Consortium for procedures on how to apply for access.
We welcome collaboration with other investigators in-
volved in cGVHD research.ACKNOWLEDGMENTS
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